Statistiche di base
| CIK | 1832415 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Better Therapeutics, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 001-39864 Commission File Number BETTER THERAPEUTICS, INC. (Exact name of registrant as specified i |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 23, 2024. As filed with the Securities and Exchange Commission on May 23, 2024. Registration No. 333-276030 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-1 Registration No. 333-276030 UNDER THE SECURITIES ACT OF 1933 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 85-3472546 (State or other jur |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 23, 2024. As filed with the Securities and Exchange Commission on May 23, 2024. Registration No. 333-271301 Registration No. 333-271302 Registration No. 333-273861 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-3 Registration No. 333-271301 Form S-3 Registration No. 333-271302 Form S-3 Registration No. 333-273861 UNDER THE SECURITIES ACT OF |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 23, 2024. As filed with the Securities and Exchange Commission on May 23, 2024. Registration No. 333-271301 Registration No. 333-271302 Registration No. 333-273861 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-3 Registration No. 333-271301 Form S-3 Registration No. 333-271302 Form S-3 Registration No. 333-273861 UNDER THE SECURITIES ACT OF |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 23, 2024. As filed with the Securities and Exchange Commission on May 23, 2024. Registration No. 333-271013 Registration No. 333-262096 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-8 Registration No. 333-271013 Form S-8 Registration No. 333-262096 UNDER THE SECURITIES ACT OF 1933 BETTER THERAPEUTICS, INC. (Exact name of registrant as specifi |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 23, 2024. As filed with the Securities and Exchange Commission on May 23, 2024. Registration No. 333-261383 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO: Form S-1 Registration No. 333-261383, as amended by Post-Effective Amendment No. 1 and by Post-Effective Amendment No. 2 on Form S-3 UNDER THE SECURITIES ACT OF 1933 BETTER THERAPEUTICS, INC. (Ex |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 23, 2024. As filed with the Securities and Exchange Commission on May 23, 2024. Registration No. 333-271301 Registration No. 333-271302 Registration No. 333-273861 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-3 Registration No. 333-271301 Form S-3 Registration No. 333-271302 Form S-3 Registration No. 333-273861 UNDER THE SECURITIES ACT OF |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 23, 2024. As filed with the Securities and Exchange Commission on May 23, 2024. Registration No. 333-271013 Registration No. 333-262096 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-8 Registration No. 333-271013 Form S-8 Registration No. 333-262096 UNDER THE SECURITIES ACT OF 1933 BETTER THERAPEUTICS, INC. (Exact name of registrant as specifi |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 (March 15, 2024) BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorpor |
|
| March 21, 2024 |
Up to 20,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276030 PROSPECTUS SUPPLEMENT NO. 4 (to prospectus dated December 27, 2023) Up to 20,000,000 Shares of Common Stock This prospectus supplement no. 4 (this “prospectus supplement”) amends and supplements the prospectus dated December 27, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms a part of our Registration S |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2024 (March 14, 2024) BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorpor |
|
| March 15, 2024 |
Up to 20,000,000 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276030 PROSPECTUS SUPPLEMENT NO. 3 (to prospectus dated December 27, 2023) Up to 20,000,000 Shares of Common Stock This prospectus supplement no. 3 (this “prospectus supplement”) amends and supplements the prospectus dated December 27, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms a part of our Registra |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commissio |
|
| March 14, 2024 |
Up to 20,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276030 PROSPECTUS SUPPLEMENT NO. 2 (to prospectus dated December 27, 2023) Up to 20,000,000 Shares of Common Stock This prospectus supplement no. 2 (this “prospectus supplement”) amends and supplements the prospectus dated December 27, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms a part of our Registration S |
|
| March 14, 2024 |
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq EX-99.1 Exhibit 99.1 Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq March 14, 2024 Better Therapeutics, Inc. (NASDAQ: BTTX) (the “Company”) announced today that the Company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the Company. This decision was ma |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commissio |
|
| March 11, 2024 |
Exhibit 99.1 Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases March 2024 Property of Better Therapeutics, Inc. Not for distribution. Disclaimer This presentation (“Presentation”) is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. (“BetterTX” or the Company“) nor any of its respecti |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commission |
|
| March 4, 2024 |
Exhibit 99.1 Transcript: Better Therapeutics CEO Interview with RedChip Filmed on Wednesday, February 14, 2024 Aired on Saturday, March 2, 2024 Dave 00:00 All right. Thanks for being with us today. 00:02 Well, thanks for having me. I’m excited to be here. Dave 00:04 Well, we’re excited to represent you. You’re the CEO of Better Therapeutics. And you have a phenomenal background. You’re a former Go |
|
| March 1, 2024 |
Better Therapeutics, Inc. 548 Market Street #49404 San Francisco, California 94104 RW Better Therapeutics, Inc. 548 Market Street #49404 San Francisco, California 94104 March 1, 2024 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Better Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-268706) Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Se |
|
| February 13, 2024 |
SC 13G/A 1 formsc13ga.htm FORM SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Better Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 08773T104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the App |
|
| February 12, 2024 |
EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13D/A filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the securities of Better Therapeutics, Inc., is being filed, and all amendments thereto will be filed, on behalf of each of the pe |
|
| February 12, 2024 |
EX-99.10 4 d728715dex9910.htm EX-99.10 Exhibit 99.10 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Georgianna Maule-Ffinch, Frank Karbe, Leslie Miller and Shoaib Ghias, Esq., signing singly, and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned’s capacity a |
|
| February 12, 2024 |
EX-99.9 3 d728715dex999.htm EX-99.9 Exhibit 99.9 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of February 9, 2024, between Better Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREA |
|
| February 12, 2024 |
SC 13D/A 1 d728715dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Better Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 08773T 104 (CUSIP Number) David P. Perry c/o Better Therapeutics, Inc. 548 Market Street, #49404 San Francisc |
|
| February 6, 2024 |
Exhibit 4.6 FORM OF COMMON WARRANT BETTER THERAPEUTICS, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: [●] Number of Shares of Common Stock: [●] Date of Issuance: [●], 2024 (“Issuance Date”) Better Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●], the registe |
|
| February 6, 2024 |
Form of Underwriting Agreement. Exhibit 1.1 [●] Shares of Common Stock (or Pre-Funded Warrants to Purchase Shares of Common Stock in Lieu Thereof) Warrants to Purchase [●] Shares of Common Stock BETTER THERAPEUTICS, INC. UNDERWRITING AGREEMENT [●], 2024 CHARDAN CAPITAL MARKETS, LLC 17 State Street, Suite 2130 New York, NY 10004 Ladies and Gentlemen: Better Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, sub |
|
| February 6, 2024 |
Table of Contents As filed with the Securities and Exchange Commission on February 6 , 2024 Registration Statement No. |
|
| February 6, 2024 |
Exhibit 4.5 FORM OF PRE-FUNDED WARRANT BETTER THERAPEUTICS, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No.: [●] Number of Shares of Common Stock: [●] Date of Issuance: [●] (“Issuance Date”) Better Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●], th |
|
| February 6, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-1 (Form Type) Better Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1)(2)(3) Fee Rate Amou |
|
| January 25, 2024 |
EX-99.1 2 d738492dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13D/A filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the securities of Better Therapeutics, Inc., is being filed, and all amendments thereto will be filed, |
|
| January 25, 2024 |
SC 13D/A 1 d738492dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Better Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 08773T 104 (CUSIP Number) David P. Perry c/o Better Therapeutics, Inc. 548 Market Street, #49404 San Francisc |
|
| January 10, 2024 |
Up to 20,406,908 Shares of Common Stock EFiled Pursuant to Rule 424(b)(3) Registration No. 333-276030 PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated December 27, 2023) Up to 20,406,908 Shares of Common Stock This prospectus supplement no. 1 (this “prospectus supplement”) amends and supplements the prospectus dated December 27, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms a part of our Registration |
|
| January 8, 2024 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of January 5, 2024, between Better Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and c |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 (January 3, 2024) Better Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or Other Jurisdiction of Incorp |
|
| January 8, 2024 |
EX-99.1 Exhibit 99.1 Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States January 3, 2024 SAN FRANCISCO & PALO ALTO, Calif.—(BUSINESS WIRE)—Jan. 3, 2024—Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, and Glooko, Inc., a gl |
|
| December 29, 2023 |
Up to 20,000,000 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-276030 PROSPECTUS Up to 20,000,000 Shares of Common Stock This prospectus relates to the potential offer and sale from time to time by Chardan Capital Markets LLC (“Chardan” or the “Selling Securityholder”) of up to 20,000,000 shares of our common stock, par value $0.0001 per share (“Common Stock”), that have been or may be is |
|
| December 27, 2023 |
As filed with the Securities and Exchange Commission on December 26, 2023 S-1/A Table of Contents As filed with the Securities and Exchange Commission on December 26, 2023 Registration No. |
|
| December 26, 2023 |
Better Therapeutics, Inc. 548 Market St #49404 San Francisco, CA 94104 Better Therapeutics, Inc. 548 Market St #49404 San Francisco, CA 94104 VIA EDGAR December 26, 2023 Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Dillon Hagius Re: Better Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-276030 Ladies and Gentlemen: Pursuant to Rule 461 under the Securi |
|
| December 22, 2023 |
Better Therapeutics, Inc. 548 Market St #49404 San Francisco, CA 94104 Better Therapeutics, Inc. 548 Market St #49404 San Francisco, CA 94104 VIA EDGAR December 22, 2023 Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Juan Grana Re: Better Therapeutics, Inc. Withdrawal of Acceleration Request for Registration Statement on Form S-1 File No. 333-276030 Mr. Grana: Reference is made to our letter, file |
|
| December 21, 2023 |
As filed with the Securities and Exchange Commission on December 21, 2023 S-1/A Table of Contents As filed with the Securities and Exchange Commission on December 21, 2023 Registration No. |
|
| December 21, 2023 |
Better Therapeutics, Inc. 548 Market St #49404 San Francisco, CA 94104 Better Therapeutics, Inc. 548 Market St #49404 San Francisco, CA 94104 VIA EDGAR December 21, 2023 Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Dillon Hagius Re: Better Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-276030 Ladies and Gentlemen: Pursuant to Rule 461 under the Securi |
|
| December 21, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Better Therapeutics, Inc. |
|
| December 18, 2023 |
As filed with the Securities and Exchange Commission on December 15, 2023 S-1/A Table of Contents As filed with the Securities and Exchange Commission on December 15, 2023 Registration No. |
|
| December 18, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Better Therapeutics, Inc. |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 (December 14, 2023) Better Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of in |
|
| December 13, 2023 |
Exhibit 10.17 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of November 27, 2023 (the “Amendment Date”), is entered into by and among Better Therapeutics, Inc., a Delaware corporation (together with its Subsidiaries that join this Agreement as “Borrower” from time to time, individually and collectively, “Borrower”) |
|
| December 13, 2023 |
EX-10.1 Exhibit 10.1 ChEF PURCHASE AGREEMENT This ChEF PURCHASE AGREEMENT is made and entered into as of December 13, 2023 (together with Annex I, this “Agreement”), by and between Chardan Capital Markets LLC, a New York limited liability company (the “Investor”), and Better Therapeutics, Inc., a Delaware corporation (the “Company”). RECITALS WHEREAS, the parties desire that, upon the terms and su |
|
| December 13, 2023 |
EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 13, 2023 is by and between Chardan Capital Markets LLC, a New York limited liability company (the “Investor”), and Better Therapeutics, Inc., a Delaware corporation (the “Company”). RECITALS The Company and the Investor have entered into that certain ChEF Purchase Agreemen |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commis |
|
| December 13, 2023 |
Table of Contents As filed with the Securities and Exchange Commission on December 1 3 , 2023 Registration No. |
|
| December 13, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Better Therapeutics, Inc. |
|
| November 30, 2023 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 (November 27, 2023) BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of in |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 (November 14, 2023) Better Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or Other Jurisdiction of In |
|
| November 9, 2023 |
Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates Company obtained FDA authorization for AspyreRxTM to treat adults with type 2 diabetes and announced commercial launch Company to host a conference call and webcast today at 8:30 a. |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 Better Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q 540 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39864 BETTER THERAPEUTICS, INC. |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 (October 27, 2023) Better Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or Other Jurisdiction of Inco |
|
| October 27, 2023 |
Table of Contents As filed with the Securities and Exchange Commission on October 2 7 , 2023 Registration Statement No. |
|
| October 27, 2023 |
EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-1 (Form Type) Better Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1)(2)(3 |
|
| October 16, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 12, 2023 |
As filed with the Securities and Exchange Commission on October 12, 2023 As filed with the Securities and Exchange Commission on October 12, 2023 Registration No. |
|
| October 12, 2023 |
Better Therapeutics, Inc. 548 Market St #49404 San Francisco, CA 94104 Better Therapeutics, Inc. 548 Market St #49404 San Francisco, CA 94104 VIA EDGAR October 12, 2023 Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Nicholas O’Leary Re: Better Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-273861 Dear Mr. O’Leary Pursuant to Rule 461 under the Securitie |
|
| October 6, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| August 25, 2023 |
As filed with the Securities and Exchange Commission on August 25, 2023 S-3/A Table of Contents As filed with the Securities and Exchange Commission on August 25, 2023 Registration No. |
|
| August 14, 2023 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Better Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 08773T 104 (CUSIP Number) David P. Perry c/o Better Therapeutics, Inc. 548 Market Street, #49404 San Francisco, CA 94104 (415) 887-2311 (Na |
|
| August 14, 2023 |
Joint Filing Agreement, as required by Rule 13d-1(k)(1) under the Exchange Act. EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13D/A filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the securities of Better Therapeutics, Inc., is being filed, and all amendments thereto will be filed, on behalf of each of the pe |
|
| August 10, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Better Therapeutics, Inc. |
|
| August 10, 2023 |
As filed with the Securities and Exchange Commission on August 9, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on August 9, 2023 Registration No. |
|
| August 9, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-271301 PROSPECTUS SUPPLEMENT (To Prospectus dated April 25, 2023) Up to $3,476,781 Common Stock We have entered into an ATM Sales Agreement, or the Sales Agreement, with Virtu Americas LLC, or the Sales Agent, relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus supplement and t |
|
| August 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2023 Better Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 9, 2023 |
Better Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates Obtained FDA Authorization for AspyreRxTM to treat adults with type 2 diabetes Established price and launch metrics in preparation for expected launch in Q4 Completed financing transactions totaling $12. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q 540 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39864 BETTER THERAPEUTICS, INC. |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Better Therapeutics Inc. |
|
| July 26, 2023 |
Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share EX-99.1 Exhibit 99.1 Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share SAN FRANCISCO—July. 25, 2023— Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing software to treat cardiometabolic diseases, today announced that it issued 2,023,583 shares of its common stock under its At-The-Market program at an average price per share of $1.19. |
|
| July 26, 2023 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of July 25, 2023, between Better Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| July 26, 2023 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of July 25, 2023, between Better Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2023 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commission |
|
| July 26, 2023 |
3,859,649 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-271301 PROSPECTUS SUPPLEMENT (To Prospectus dated April 25, 2023) 3,859,649 Shares of Common Stock We are offering 3,859,649 shares of our common stock in a registered direct offering directly to a single investor at a price per share of $0.57 pursuant to this prospectus supplement and the accompanying prospectus and a s |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 Better Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 12, 2023 |
Exhibit 99.1 Better Therapeutics Receives FDA Authorization for AspyreRxTM to Treat Adults with Type 2 Diabetes First prescription digital behavioral therapeutic device delivering novel form of cognitive behavioral therapy via smartphone In a randomized controlled trial AspyreRx demonstrated clinically meaningful and statistically significant durable reductions in A1c Company to host conference ca |
|
| July 12, 2023 |
Corporate Presentation of Better Therapeutics, Inc., dated June 11, 2023. owerpoint Exhibit 99.2 |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 Better Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 07, 2023 Better Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Better Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 11, 2023 |
EX-10.1 Exhibit 10.1 BETTER THERAPEUTICS, INC. Common Stock (par value $0.0001 per share) ATM Sales Agreement May 11, 2023 Virtu Americas LLC 1633 Broadway New York, NY 10019 Ladies and Gentlemen: Better Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Virtu Americas LLC (the “Agent”) as follows: 1. Issuance and Sale of Shares. The Company |
|
| May 11, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commission |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q 540 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39864 BETTER THERAPEUTICS, INC. |
|
| May 11, 2023 |
Better Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates On track for an FDA decision mid-year Announced restructuring to extend cash runway Completed private placement financing Company to host conference call and webcast today at 8:30 a. |
|
| May 11, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-271301 PROSPECTUS SUPPLEMENT (To Prospectus dated April 25, 2023) Up to $6,890,142 Common Stock We have entered into an ATM Sales Agreement, or the Sales Agreement, with Virtu Americas LLC, or the Sales Agent, relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus supplement and t |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 Better Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 21, 2023 |
Better Therapeutics, Inc. 548 Market St #49404 San Francisco, CA 94104 CORRESP Better Therapeutics, Inc. 548 Market St #49404 San Francisco, CA 94104 VIA EDGAR April 21, 2023 Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Benjamin Richie Re: Better Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-271302 Dear Mr. Richie: Pursuant to Rule 461 under the Secu |
|
| April 21, 2023 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Better Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 08773T 104 (CUSIP Number) David P. Perry c/o Better Therapeutics, Inc. 548 Market Street, #49404 San Francisco, CA 94104 (415) 887-2311 (Na |
|
| April 21, 2023 |
EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the securities of Better Therapeutics, Inc., is being filed, and all amendments thereto will be filed, on behalf of each of the pers |
|
| April 21, 2023 |
Better Therapeutics, Inc. 548 Market St #49404 San Francisco, CA 94104 CORRESP Better Therapeutics, Inc. 548 Market St #49404 San Francisco, CA 94104 VIA EDGAR April 21, 2023 Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Benjamin Richie Re: Better Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-271301 Dear Mr. Richie: Pursuant to Rule 461 under the Secu |
|
| April 18, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Better Therapeutics, Inc. |
|
| April 18, 2023 |
Power of Attorney (included on signature page). S-3 Table of Contents As filed with the Securities and Exchange Commission on April 17, 2023 Registration No. |
|
| April 18, 2023 |
As filed with the Securities and Exchange Commission on April 17, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on April 17, 2023 Registration No. |
|
| April 18, 2023 |
Form of Senior Indenture between Better Therapeutics, Inc. and one or more trustees to be named. EX-4.9 Exhibit 4.9 BETTER THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Truste |
|
| April 18, 2023 |
EX-4.10 Exhibit 4.10 BETTER THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS(1) Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Tr |
|
| April 18, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Better Therapeutics, Inc. |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commissio |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* Better Therapeutics, Inc. (f/k/a Mountain Crest Acquisition Corp. II) (Name of Issuer) Common Stock, par value $0.0001 per Share (Title of Class of Securities) 08773T104 (CUSIP Number) April 10, 2023 (Date of Event which Requires Filing of this Statement |
|
| April 7, 2023 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of April 6, 2023, between Better Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con |
|
| April 7, 2023 |
Better Therapeutics Announces $6.5MM Private Placement EX-99.1 Exhibit 99.1 Better Therapeutics Announces $6.5MM Private Placement SAN FRANCISCO—April 06, 2023— Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced a private placement of 7,878,7 |
|
| April 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2023 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commission |
|
| April 7, 2023 |
EX-10.2 Exhibit 10.2 EXECUTION VERSION FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of April 5, 2023 (the “Amendment Date”), is entered into by and among Better Therapeutics, Inc., a Delaware corporation (together with its Subsidiaries that join this Agreement as “Borrower” from time to time, individually and collec |
|
| March 31, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 POS AM Table of Contents As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 31, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 S-8 As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 31, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Better Therapeutics, Inc. |
|
| March 31, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Better Therapeutics, Inc. |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commissio |
|
| March 30, 2023 |
BETTER THERAPEUTICS, INC. 2022 INDUCEMENT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Better Therapeutics, Inc. 2022 Inducement Plan (the “Plan”). The purpose of the Plan is to enable Better Therapeutics, Inc. (the “Company”) to grant equity awards to induce highly-qualified prospective officers and employees who are not currently employed by the Company an |
|
| March 30, 2023 |
v UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39864 BETTER THERAP |
|
| March 30, 2023 |
EX-99.1 Exhibit 99.1 Better Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates Advanced preparations for potential commercial launch of BT-001 in U.S. in mid-2023 Reported positive topline results from exploratory trial for fatty liver disease Announced restructuring and other cost saving actions to extend financial runway Company to host confere |
|
| March 24, 2023 |
Excerpt from Email to Better Therapeutics, Inc. Employees on March 23, 2023 EX-99.1 Exhibit 99.1 Excerpt from Email to Better Therapeutics, Inc. Employees on March 23, 2023 Hello Team, Today was a painful day. I announced earlier we are taking several actions to ensure the long-term success of our company. Sadly, these actions included a reduction in force impacting approximately 35% of our colleagues. We are also implementing other cost savings measures to further extend |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commissio |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commissio |
|
| February 7, 2023 |
SC 13G/A 1 13ga2bettertx.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) * Better Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 08773T104 (Cusip Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the a |
|
| December 12, 2022 |
EX-99.1 Exhibit 99.1 Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results Study Conducted with Arizona Liver Health Met Primary Endpoint and Established Proof-of-Concept for Prescription Digital Therapy Platform to Improve Disease Biomarkers in NAFLD and NASH Patients Company Intends to Apply for Breakthrough Device Designation with FDA Com |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commiss |
|
| December 12, 2022 |
DECEMBER 8, 2022 LivVita Liver Health Feasibility Study Topline Data Better+ T HERA PEU TICS EX-99.2 Exhibit 99.2 DECEMBER 8, 2022 LivVita Liver Health Feasibility Study Topline Data Better+ T HERA PEU TICS Disclaimer This presentation (“Presentation”) is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. (“BetterTX” or the “Company”) nor any of its respective affiliates nor any of its or their contr |
|
| December 7, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on December 7 , 2022 Registration Statement No. |
|
| December 7, 2022 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Better Therapeutics, Inc. |
|
| November 16, 2022 |
Up to 20,406,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-261383 PROSPECTUS SUPPLEMENT NO. 7 (to prospectus dated April 6, 2022) Up to 20,406,908 Shares of Common Stock This prospectus supplement no. 7 (this ?prospectus supplement?) amends and supplements the prospectus dated April 6, 2022 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Statement |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q 540 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39864 BETTER THERAPEUTICS, INC. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commis |
|
| November 14, 2022 |
EX-99.1 Exhibit 99.1 Better Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates U.S. FDA accepted the company’s submission of its de novo request for BT-001 investigational prescription digital therapy for type 2 diabetes in adults BT-001 pivotal clinical trial 90-day results published in peer-reviewed journal Diabetes Care Appointed highly experienced healthcar |
|
| November 2, 2022 |
EX-99.1 Exhibit 99.1 Better Therapeutics Appoints Diane Gomez-Thinnes as Chief Commercial Officer Industry Veteran Joins Health Technology Pioneer to Bring Prescription Digital Therapeutics for Type 2 Diabetes and other Cardiometabolic Conditions to Market SAN FRANCISCO, Oct. 27, 2022 – Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a novel f |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commiss |
|
| September 22, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2022 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commi |
|
| September 22, 2022 |
Exhibit 99.1 Better Therapeutics Submits De Novo Request to U.S. FDA for BT-001 Investigational Prescription Digital Therapy for Type 2 Diabetes Submission follows completion of first-in-class trial demonstrating significant improvements in A1c reduction with investigational therapy targeting the root causes of type 2 diabetes. SAN FRANCISCO, September 22, 2022 ? Better Therapeutics, Inc. (NASDAQ: |
|
| September 14, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2022 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commi |
|
| September 14, 2022 |
Exhibit 99.1 Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases SEPTEMBER 2022 Disclaimer This presentation (?Presentation?) is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. (?BetterTX? or the Company?) nor any of its respective affiliates nor any of its or their control persons, o |
|
| August 11, 2022 |
Exhibit 99.1 Better Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update Completed pivotal trial of BT-001 for type 2 diabetes and reported positive secondary endpoint results after 180 days of treatment On track to submit de novo classification request for BT-001 with FDA in third quarter of 2022 Completed enrollment in LivVita Liver Study for nonalcoholic fatt |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commissi |
|
| August 11, 2022 |
Up to 20,406,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-261383 PROSPECTUS SUPPLEMENT NO. 6 (to prospectus dated April 6, 2022) Up to 20,406,908 Shares of Common Stock This prospectus supplement no. 6 (this ?prospectus supplement?) amends and supplements the prospectus dated April 6, 2022 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Statement |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q 540 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39864 BETTER THERAPEUTICS, INC. |
|
| July 28, 2022 |
Exhibit 99.1 Better Therapeutics Completes Pivotal Trial of BT-001 for Type 2 Diabetes and Announces Positive Secondary Endpoint Results Following the Earlier Announcement of Positive Primary Endpoint Results Data demonstrates BT-001 was durable with A1c reductions continuing to improve after 180 days of treatment On track to submit a de novo classification request with FDA for BT-001 in third qua |
|
| July 28, 2022 |
Exhibit 99.2 JULY 28, 2022 BT-001 Pivotal Clinical Trial Results Disclaimer This presentation (?Presentation?) is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. (?BetterTX? or the Company?) nor any of its respective affiliates nor any of its or their control persons, officers, directors, employees or repr |
|
| July 28, 2022 |
Up to 20,406,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-261383 PROSPECTUS SUPPLEMENT NO. 5 (to prospectus dated April 6, 2022) Up to 20,406,908 Shares of Common Stock This prospectus supplement no. 5 (this ?prospectus supplement?) amends and supplements the prospectus dated April 6, 2022 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Statement |
|
| July 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2022 BETTER THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commission |
|
| June 13, 2022 |
Up to 20,406,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-261383 PROSPECTUS SUPPLEMENT NO. 4 (to prospectus dated April 6, 2022) Up to 20,406,908 Shares of Common Stock This prospectus supplement no. 4 (this ?prospectus supplement?) amends and supplements the prospectus dated April 6, 2022 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Statement |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commission |
|
| June 13, 2022 |
Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (?Agreement?) is made by and between Kevin Appelbaum (?Executive?), Kevin Appelbaum, or his successor(s), as Trustee of The Kevin Appelbaum Revocable Trust under Revocable Trust Declaration dated May 16, 2020, as amended (?Executive?s Trust?), Better Therapeutics OpCo, Inc., a Delaware corporation (together with it |
|
| June 13, 2022 |
Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Better Therapeutics OpCo, Inc., a Delaware corporation (the ?Company?), Better Therapeutics, Inc., a Delaware corporation and the sole stockholder of the Company (the ?Parent? and collectively with the Company, the ?Companies?) and Frank Karbe (the ?Executive?) and is effective as of July 5, 2022 (the ?Effect |
|
| June 7, 2022 |
Up to 20,406,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-261383 PROSPECTUS SUPPLEMENT NO. 3 (to prospectus dated April 6, 2022) Up to 20,406,908 Shares of Common Stock This prospectus supplement no. 3 (this ?prospectus supplement?) amends and supplements the prospectus dated April 6, 2022 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Statement |
|
| June 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commission |
|
| June 7, 2022 |
Better Therapeutics Appoints Frank Karbe as Chief Executive Officer Exhibit 99.1 Better Therapeutics Appoints Frank Karbe as Chief Executive Officer SAN FRANCISCO, June 7, 2022 ? Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join the company as President and Chief Exec |
|
| May 13, 2022 |
Exhibit 99.2 Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases MAY 2022 Disclaimer This presentation (?Presentation?) is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. (?BetterTx? or the Company?) nor any of its respective affiliates nor any of its or their control persons, officer |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q 540 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39864 BETTER THERAPEUTICS, INC. |
|
| May 13, 2022 |
Up to 20,406,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-261383 PROSPECTUS SUPPLEMENT NO. 2 (to prospectus dated April 6, 2022) Up to 20,406,908 Shares of Common Stock This prospectus supplement no. 2 (this ?prospectus supplement?) amends and supplements the prospectus dated April 6, 2022 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Statement |
|
| May 13, 2022 |
Up to 20,406,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-261383 PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated April 6, 2022) Up to 20,406,908 Shares of Common Stock This prospectus supplement no. 1 (this ?prospectus supplement?) amends and supplements the prospectus dated April 6, 2022 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Statement |
|
| May 13, 2022 |
Exhibit 99.1 Better Therapeutics Reports First Quarter 2022 Financial Results and Provides Update on Key Corporate Milestones Reported positive primary endpoint results from pivotal trial of BT-001 after 90 days of treatment for type 2 diabetes Represents a first-in-class randomized, controlled clinical trial of a prescription digital therapeutic (PDT) for treating a cardiometabolic disorder Data |
|
| May 13, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commission |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 7, 2022 |
Up to 20,406,908 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-261383 PROSPECTUS Up to 20,406,908 Shares of Common Stock This prospectus relates to the offer and sale, from time to time, by the selling stockholders named in this prospectus (the ?Selling Stockholders?), or any of their pledgees, donees, assignees and successors-in-interest (?permitted transferees?), of (i) up to |
|
| April 1, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on April 1, 2022 Registration Statement No. |
|
| March 28, 2022 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the capital stock of Better Therapeutics, Inc. (the ?Company,? ?we,? ?us,? and ?our?) is a summary of certain provisions of the securities that are registered under Section 12 of the Securities and Exchange Act of 1934, as amended, and does no |
|
| March 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commissio |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K v UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39864 BETTER THERAP |
|
| March 28, 2022 |
Exhibit 99.1 Better Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results Company Highlights Positive Pivotal Clinical Trial Data for BT-001, a Prescription Digital Therapeutic for Type 2 Diabetes SAN FRANCISCO, March 28, 2022 ? Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) |
|
| March 15, 2022 |
Up to 20,406,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-261383 PROSPECTUS SUPPLEMENT NO. 3 (to prospectus dated December 8, 2021) Up to 20,406,908 Shares of Common Stock This prospectus supplement no. 3 (this ?prospectus supplement?) amends and supplements the prospectus dated December 8, 2021 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Sta |
|
| March 15, 2022 |
Up to 20,406,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-261383 PROSPECTUS SUPPLEMENT NO. 2 (to prospectus dated December 8, 2021) Up to 20,406,908 Shares of Common Stock This prospectus supplement no. 2 (this ?prospectus supplement?) amends and supplements the prospectus dated December 8, 2021 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Sta |
|
| March 15, 2022 |
Exhibit 99.1 Better Therapeutics Announces Positive Primary Endpoint Data from Pivotal Clinical Trial of BT-001, a Prescription Digital Therapeutic (PDT) for Patients with Uncontrolled Type 2 Diabetes Data Demonstrates Clinically Meaningful and Statistically Significant Results, Improving Glycemic Control by Reducing A1c 0.4% Versus the Control Group Receiving Standard of Care SAN FRANCISCO, March |
|
| March 15, 2022 |
MARCH 15, 2022 Primary Endpoint Day 90 Analysis Better+ THERAPEUTICS Exhibit 99.1 MARCH 15, 2022 Primary Endpoint Day 90 Analysis Better+ THERAPEUTICS Disclaimer This presentation (?Presentation?) is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. (?BetterTX? or the ?Company?) nor any of its respective affiliates nor any of its or their control persons, officers, directors, |
|
| March 15, 2022 |
Exhibit 99.2 Exhibit 99.2 MARCH 15, 2022 Primary Endpoint Day 90 Analysis Disclaimer This presentation (?Presentation?) is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. (?BetterTX? or the ?Company?) nor any of its respective affiliates nor any of its or their control persons, officers, directors, employe |
|
| March 15, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 BETTER THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incor |
|
| March 15, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 BETTER THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commissio |
|
| February 10, 2022 |
Mountain Crest Acquisition Corp. II / Mountain Crest Capital LLC - SC 13G Passive Investment SC 13G 1 tm225924d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 Better Therapeutics, Inc. (f/k/a Mountain Crest Acquisition Corp. II) (Name of Issuer) Common Stock, par value $0.0001 per Sh |
|
| February 10, 2022 |
US08773T1043 / Mountain Crest Acquisition Corp. II / RPO LLC - RPO LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BETTER THERAPEUTICS INC. (f/k/a Mountain Crest Acquisition Corp. II) (Name of Issuer) 0.0001 (Title of Class of Securities) 08773T104 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 10, 2022 |
Mountain Crest Acquisition Corp. II / BOOTHBAY FUND MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Better Therapeutics, Inc. (f/k/a/ Mountain Crest Acquisition Corp. II) (Name of Issuer) Common Stock (Title of Class of Securities) 62402D204 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate b |
|
| February 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 18, 2022 |
Mountain Crest Acquisition Corp. II / K2 PRINCIPAL FUND, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A (Rule 13d-102) Amendment No. 1 Under the Securities Exchange Act of 1934 Better Therapeutics fka. Mountain Crest Acquisition Corp. II (Name of Issuer) Common stock. $0.0001 par value (Title of Class of Securities) 62402D204 (CUSIP Number) October 28, 2021 (Date of Event which Requires Filing of this Statement) C |
|
| January 14, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2021 BETTER THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of in |
|
| January 14, 2022 |
Letter dated January 14, 2022 from Marcum LLP to Securities and Exchange Commission Exhibit 16.1 January 14, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Better Therapeutics, Inc. (formerly Mountain Crest Acquisition Corp. II) under Item 4.01 of its Form 8-K/A dated January 14, 2022. We agree with the statements concerning our Firm in such Form 8-K/A; we are not in a position to agree or disagre |
|
| January 14, 2022 |
Up to 20,406,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-261383 PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated December 8, 2021) Up to 20,406,908 Shares of Common Stock This prospectus supplement no. 1 (this ?prospectus supplement?) amends and supplements the prospectus dated December 8, 2021 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Sta |
|
| January 11, 2022 |
As filed with the Securities and Exchange Commission on January 11, 2022 As filed with the Securities and Exchange Commission on January 11, 2022 Registration No. |
|
| December 10, 2021 |
Up to 20,406,908 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-261383 PROSPECTUS Up to 20,406,908 Shares of Common Stock This prospectus relates to the offer and sale, from time to time, by the selling stockholders named in this prospectus (the ?Selling Stockholders?), or any of their pledgees, donees, assignees and successors-in-interest (?permitted transferees?), of (i) up to an aggrega |
|
| December 6, 2021 |
Better Therapeutics, Inc. 548 Market St #49404 San Francisco, CA 94104 Better Therapeutics, Inc. 548 Market St #49404 San Francisco, CA 94104 VIA EDGAR December 6, 2021 Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Dillon Hagius Re: Better Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-261383 Ladies and Gentlemen: Pursuant to Rule 461 under the Securit |
|
| November 29, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on November 2 6 , 2021 Registration Statement No. |
|
| November 26, 2021 |
Exhibit 16.1 November 24, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Better Therapeutics, Inc. (formerly Mountain Crest Acquisition Corp. II) under Item 4.01 of its Form 8-K dated November 24, 2021. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree |
|
| November 26, 2021 |
Exhibit 99.2 Management?s Discussion and Analysis of Financial Condition and Results of Operations. Results of Operations Comparisons of the three and nine months ended September 30, 2021 and 2020 The following table summarizes our results of operations for the periods presented (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 % Change 2021 2020 % Change R |
|
| November 26, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 BETTER THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of inc |
|
| November 26, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma combined financial information present the combination of the financial information of MCAD and BTX adjusted to give effect to the Business Combination Introduction MCAD is providing the following unaudited pro forma condensed combined financial information to assist in your analysis and eval |
|
| November 26, 2021 |
Exhibit 99.3 BETTER THERAPEUTICS, INC. UNAUDITED BALANCE SHEETS (in thousands, except share data) September 30, December 31, 2021 2020 ASSETS Current assets: Cash and cash equivalents $ 3,232 $ 123 Prepaid expenses 268 124 Deferred offering costs 1,904 ? Other current assets 214 216 Total current assets 5,618 463 Capitalized software development costs, net 5,114 5,555 Property and equipment, net 6 |
|
| November 26, 2021 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2021 BETTER THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commis |
|
| November 23, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001- |
|
| November 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 BETTER THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commis |
|
| November 18, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2021 BETTER THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commis |
|
| November 18, 2021 |
Exhibit 99.1 Better Therapeutics Completes Enrollment of Pivotal Trial for BT-001, a Prescription Digital Therapeutic for Type 2 Diabetes Primary endpoint data expected in Q1 2022 SAN FRANCISCO, November 18, 2021 ? Better Therapeutics, Inc. (?Better Therapeutics?; NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardio |
|
| November 18, 2021 |
Exhibit 99.2 COMPANY PRESENTATION | NOVEMBER 2021 Disclaimer This presentation (?Presentation?) is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. (?BetterTX? or the Company?) nor any of its respective affiliates nor any of its or their control persons, officers, directors, employees or representatives mak |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 BETTER THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) (Commis |
|
| November 17, 2021 |
Exhibit 99.1 Better Therapeutics Appoints Major General Elder Granger, M.D., U.S. Army (retired) to its Board of Directors November 11, 2021 Better Therapeutics, Inc. (?Better Therapeutics?; NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Major General Elder |
|
| November 15, 2021 |
SEC FILE NUMBER 001-39864 CUSIP NUMBER 08773T 104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 8, 2021 |
SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.)* Better Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 08773T 104 (CUSIP Number) Kevin J. Appelbaum c/o Better Therapeutics, Inc. 548 Market Street, #49404 San Francisco, CA 94104 (415) 887-2311 (Na |
|
| November 8, 2021 |
MCAD / Mountain Crest Acquisition Corp. II / David P. Perry 2015 Trust - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.)* Better Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 08773T 104 (CUSIP Number) David P. Perry c/o Better Therapeutics, Inc. 548 Market Street, #49404 San Francisco, CA 94104 (415) 887-2311 (Name, |
|
| November 8, 2021 |
Joint Filing Agreement, as required by Rule 13d-1(k)(1) under the Exchange Act. EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the securities of Better Therapeutics, Inc., is being filed, and all amendments thereto will be filed, on behalf of the person and e |
|
| November 8, 2021 |
JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) EXHIBIT 1 to SCHEDULE 13G JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition st |
|
| November 8, 2021 |
Joint Filing Agreement, as required by Rule 13d-1(k)(1) under the Exchange Act. EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the securities of Better Therapeutics, Inc., is being filed, and all amendments thereto will be filed, on behalf of each of the pers |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 3, 2021 |
EX-10.1 4 d222276dex101.htm EX-10.1 Exhibit 10.1 BETTER THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Better Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Better Therapeutics, Inc. (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of the Company’s common stoc |
|
| November 3, 2021 |
Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MOUNTAIN CREST ACQUISITION CORP. II Mountain Crest Acquisition Corp. II, a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Mountain Crest Acquisition Corp. II. The date of the filing of its original Certificate of Inc |
|
| November 3, 2021 |
Code of Business Conduct and Ethics, adopted on October 28, 2021 Exhibit 16.1 BETTER THERAPEUTICS, INC. Code of Business Conduct and Ethics I. Purpose and Scope The Board of Directors of Better Therapeutics, Inc. (together with its subsidiaries, the ?Company?) has adopted this Code of Business Conduct and Ethics (this ?Code?) to aid the Company?s directors, officers and employees in making ethical and legal decisions when conducting the Company?s business and p |
|
| November 3, 2021 |
Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization Better Therapeutics OpCo, Inc. Delaware |
|
| November 3, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS EX-99.1 16 d222276dex991.htm EX-99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS MCAD is providing the following unaudited pro forma combined financial information to aid you in your analysis of the financial aspects of the Business Combination. The following unaudited pro forma combined financial information present the combination of the financial information of MCAD |
|
| November 3, 2021 |
Exhibit 10.16 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) effective as of the 28th day of October, 2021, is made and entered into by and among Better Therapeutics, Inc. (formerly known as Mountain Crest Acquisition Corp II), a Delaware corporation (the ?Company?), each of the undersigned parties that are Pre-IPO Inve |
|
| November 3, 2021 |
Exhibit 10.3 BETTER THERAPEUTICS, INC. 2020 STOCK OPTION AND GRANT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Better Therapeutics, Inc. 2020 Stock Option and Grant Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of Better Therapeutics, Inc., a Delaware corporation ( |
|
| November 3, 2021 |
Exhibit 10.9 BETTER THERAPEUTICS, INC. October 28, 2021 David Perry E-mail Re: Executive Chairperson for Better Therapeutics, Inc. Dear David: We are very pleased to offer you the position of Executive Chairperson of the Board of Directors (the ?Board?) of Better Therapeutics, Inc. (?Company? or ?We?) at a time commitment of approximately 20 hours per week. This position will report to the Board. |
|
| November 3, 2021 |
Exhibit 10.17 SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this ?Subscription Agreement?) is entered into on October 28, 2021, by and between Mountain Crest Acquisition Corp. II, a Delaware corporation (?MCAD?), and Cowen and Company, LLC (the ?Cowen?). WHEREAS, this Subscription Agreement is being entered into in connection with the Agreement and Plan of Merger, dated as of the date hereof |
|
| November 3, 2021 |
Exhibit 10.5 BETTER THERAPEUTICS, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the ?Incentive Plan?) is intended to provide an incentive for superior work and to motivate eligible executives of Better Therapeutics, Inc. (the ?Company?) and its subsidiaries toward even higher achievement and business results, to tie their goals and inte |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 BETTER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39864 86-3165029 (State or other jurisdiction of incorporation) (Commiss |
|
| November 3, 2021 |
Exhibit 10.2 BETTER THERAPEUTICS, INC. 2021 STOCK OPTION AND INCENTIVE PLAN, AS AMENDED SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Better Therapeutics, Inc. 2021 Stock Option and Incentive Plan (as amended from time to time, the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Better |
|
| November 3, 2021 |
Exhibit 10.8 BETTER THERAPEUTICS, INC. FORM OF OFFICER INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of [] by and between Better Therapeutics, Inc., a Delaware corporation (the ?Company?), and [Officer] (?Indemnitee?). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Compan |
|
| November 3, 2021 |
Exhibit 10.7 BETTER THERAPEUTICS, INC. FORM OF DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of [] by and between Better Therapeutics, Inc., a Delaware corporation (the ?Company?), and [Director] (?Indemnitee?). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Comp |
|
| November 3, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF BETTER THERAPEUTICS, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors of the Corporation (the ?Board |
|
| November 3, 2021 |
Exhibit 10.6 BETTER THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Better Therapeutics, Inc., a Delaware corporation (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of |
|
| October 29, 2021 |
Mountain Crest Acquisition Corp. II / Feis Lawrence Michael - SCHEDULE 13G Passive Investment OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number:3235-0145 Expires:Febuary 28, 2009 Estimated average burden hours per response ....10.4 SCHEDULE 13G Under the Securities and Exchange Act of 1934 (Amendment No. 1 )* Mountain Crest Acquisition Corp. II (Name of Issuer) common stock. $0.0001 par value (Title of Class of Securities) 62402D204 (CUSIP Numb |
|
| October 27, 2021 |
EX-99.1 2 tm2131053d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Mountain Crest Acquisition Corp. II Stockholders Approve Business Combination with Better Therapeutics Inc. Trading Under New Ticker Symbol “BTTX” Expected to Begin Friday, October 29, 2021 New York, NY – October 27, 2021- Mountain Crest Acquisition Corp. II (NASDAQ: MCAD) (the “Company”), a publicly traded special purpose acquisition compa |
|
| October 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 27, 2021 Date of Report (Date of earliest event reported) Mountain Crest Acquisition Corp. II (Exact Name of Registrant as Specified in its Charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) |
|
| October 27, 2021 |
Exhibit 99.1 Mountain Crest Acquisition Corp. II Stockholders Approve Business Combination with Better Therapeutics Inc. Trading Under New Ticker Symbol ?BTTX? Expected to Begin Friday, October 29, 2021 New York, NY ? October 27, 2021- Mountain Crest Acquisition Corp. II (NASDAQ: MCAD) (the ?Company?), a publicly traded special purpose acquisition company, announced today that in a special meeting |
|
| October 27, 2021 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 27, 2021 Date of Report (Date of earliest event reported) Mountain Crest Acquisition Corp. II (Exact Name of Registrant as Specified in its Charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) |
|
| October 20, 2021 |
Filed by Mountain Crest Acquisition Corp. II Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Mountain Crest Acquisition Corp. II Commission File No. 001-39864 Better Therapeutics Enrolls First Patient in Real-World Evidence Study with Catalyst Health Network Evaluating BT-001 for Type 2 Diabetes |
|
| October 13, 2021 |
Filed by Mountain Crest Acquisition Corp. II Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Mountain Crest Acquisition Corp. II Commission File No. 001-39864 Mountain Crest Acquisition Corp. II and Better Therapeutics, Inc. Announce Registration Statement Effectiveness and Scheduled Special Meet |
|
| October 12, 2021 |
TABLE OF CONTENTS ? Filed Pursuant to Rule 424(b)(3)? ?Registration No. 333-255493? PROXY STATEMENT FOR SPECIAL MEETING OF MOUNTAIN CREST ACQUISITION CORP. II AND PROSPECTUS FOR SHARES OF COMMON STOCK OF MOUNTAIN CREST ACQUISITION CORP. II Mountain Crest Acquisition Corp. II 311 West 43rd Street 12th Floor New York, NY 10036 (646) 493-6558 To the Stockholders of Mountain Crest Acquisition Corp. II |
|
| October 12, 2021 |
Mountain Crest Acquisition Corp. II 311 West 43rd Street 12th Floor New York, NY 10036 Mountain Crest Acquisition Corp. II 311 West 43rd Street 12th Floor New York, NY 10036 October 12, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Lauren Hamill Re: Mountain Crest Acquisition Corp. II Registration Statement on Form S-4 Filed April 23, 2021, as amended Registration No. 333-255493 Dear Ms. Ha |
|
| October 7, 2021 |
345 Park Avenue New York, NY 10154-1895 Direct 212.407.4000 Main 212.407.4000 Fax 212.407.4990 October 7, 2021 Division of Corporate Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: Lauren Hamill Christopher Edwards Re: Mountain Crest Acquisition Corp. II Amendment No. 4 to Registration Statement on Form S-4 Filed on October 4, 2021 File No. 333-255493 |
|
| October 7, 2021 |
As filed with the U.S. Securities and Exchange Commission on October 7, 2021 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on October 7, 2021 Registration No. 333-255493? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? ? Amendment No. 5 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933? ? Mountain Crest Acquisition Corp. II (Exact name of registrant as specified in its charter) ? ? Delaware ? ? 67 |
|
| October 4, 2021 |
As filed with the U.S. Securities and Exchange Commission on October 1, 2021 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on October 1, 2021 Registration No. 333-255493? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? ? Amendment No. 4 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933? ? Mountain Crest Acquisition Corp. II (Exact name of registrant as specified in its charter) ? ? Delaware ? ? 67 |
|
| October 4, 2021 |
Specimen Common Stock Certificate of the Combined Entity. EX-4.5 9 tm2115985d16ex4-5.htm EXHIBIT 4.5 Exhibit 4.5 0 Incorporated under the laws of the State of Delaware ****** Better Therapeutics, Inc. TOTAL AUTHORIZED ISSUE 200,000,000 SHARES PAR VALUE $0.0001 COMMON STOCK This is to Certify that ******************* is the owner of *********** * fully paid and non-assessable shares of the above Corporation transferable only on the books of the Corporatio |
|
| October 1, 2021 |
345 Park Avenue New York, NY 10154-1895 Direct 212.407.4000 Main 212.407.4000 Fax 212.407.4990 October 1, 2021 Division of Corporate Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: Lauren Hamill Christopher Edwards Re: Mountain Crest Acquisition Corp. II Amendment No. 3 to RegistrationStatement on Form S-4 Filed on September 10, 2021 File No. 333-25549 |
|
| September 28, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 27, 2021 Date of Report (Date of earliest event reported) Mountain Crest Acquisition Corp. II (Exact Name of Registrant as Specified in its Charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporatio |
|
| September 28, 2021 |
Second Amendment to Agreement and Plan of Merger dated September 27, 2021 Exhibit 2.1 SECOND AMENDMENT TO AGREEMENT AND PLAN OF MERGER THIS SECOND AMENDMENT TO AGREEMENT AND PLAN OF MERGER (this ?Amendment?) is made and entered into as of September 27, 2021 by and among Mountain Crest Acquisition Corp. II, a Delaware corporation (?Parent?), MCAD Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent (?Merger Sub?), and Better Therapeutics, Inc., a |
|
| September 27, 2021 |
MCAD / Mountain Crest Acquisition Corp. II / RPO LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MOUNTAIN CREST ACQUISITION CORP. II (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 62402D105 (CUSIP Number) September 14, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| September 27, 2021 |
EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the common stock, $0. |
|
| September 10, 2021 |
Exhibit 10.23 ? Execution Version ? LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this ?Agreement?), dated and effective as of August 18, 2021, by and among BETTER THERAPEUTICS, INC., a Delaware corporation (together with its Subsidiaries that join this Agreement as ?Borrowers? after the date hereof, individually and collectively, jointly and severally, ?Borrower?), the several ban |
|
| September 10, 2021 |
As filed with the U.S. Securities and Exchange Commission on September 9, 2021 Table of Contents As filed with the U.S. Securities and Exchange Commission on September 9, 2021 ? Registration No. 333-255493 ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Mountain Crest Acquisition Corp. II (Exact name of registrant as specified in its charter) ? Delaware 6770 85-347 |
|
| September 10, 2021 |
Filed by Mountain Crest Acquisition Corp. II Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Mountain Crest Acquisition Corp. II Commission File No. 001-39864 Better Therapeutics to Participate in Lake Street’s 5th Annual Best Ideas Growth (BIG5) Conference on September 14-15, 2021 SAN FRANCISCO, |
|
| September 10, 2021 |
Filed by Mountain Crest Acquisition Corp. II Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Mountain Crest Acquisition Corp. II Commission File No. 001-39864 Better Therapeutics Highlights Recent Progress and Updates Outlook Through 2022 Pivotal trial of BT-001 in type 2 diabetes expected to be |
|
| September 9, 2021 |
345 Park Avenue New York, NY 10154-1895 Direct 212.407.4000 Main 212.407.4000 Fax 212.407.4990 September 9, 2021 Division of Corporate Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: Joe McCann Lauren Hamill Re: Mountain Crest Acquisition Corp. II Amendment No. 2 to Registration Statement on Form S-4 Filed on August 12, 2021 File No. 333-255493 Dear Mr |
|
| September 1, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 30, 2021 Date of Report (Date of earliest event reported) Mountain Crest Acquisition Corp. II (Exact Name of Registrant as Specified in its Charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) |
|
| September 1, 2021 |
Amendment to Agreement and Plan of Merger dated August 30, 2021 Exhibit 2.1 AMENDMENT TO AGREEMENT AND PLAN OF MERGER THIS AMENDMENT TO AGREEMENT AND PLAN OF MERGER (this ?Amendment?) is made and entered into as of August 30, 2021 by and among Mountain Crest Acquisition Corp. II, a Delaware corporation (?Parent?), MCAD Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent (?Merger Sub?), and Better Therapeutics, Inc., a Delaware corpora |
|
| August 25, 2021 |
Filed by Mountain Crest Acquisition Corp. II Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Mountain Crest Acquisition Corp. II Commission File No. 001-39864 Better Therapeutics Secures $50 Million Debt Facility from Hercules Capital Provides up to $150 million in total financing in combination |
|
| August 25, 2021 |
Filed by Mountain Crest Acquisition Corp. II Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Mountain Crest Acquisition Corp. II Commission File No. 001-39864 Better Therapeutics Expands Real-World Evidence Study Initiative With Addition of Catalyst Health Network Open-label, real-world study wil |
|
| August 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 18, 2021 Date of Report (Date of earliest event reported) Mountain Crest Acquisition Corp. II (Exact Name of Registrant as Specified in its Charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) |
|
| August 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 18, 2021 Date of Report (Date of earliest event reported) Mountain Crest Acquisition Corp. II (Exact Name of Registrant as Specified in its Charter) Delaware 001-39864 85-3472546 (State or other jurisdiction of incorporation) |
|
| August 20, 2021 |
Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 17, 2021 |
Filed by Mountain Crest Acquisition Corp. II Filed by Mountain Crest Acquisition Corp. II Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Mountain Crest Acquisition Corp. II Commission File No. 001-39864 Company Name: Better Therapeutics, Inc. Event: Canaccord Genuity 41st Annual Growth Conference Date: August 12, 2021 <> Great. Good aftern |
